research use only

C188-9 (TTI-101) STAT3 inhibitor

Name: C188-9 (TTI-101)
Brand: Selleck Chemicals
SKU: S8605
Availability: InStock
Rating: 5 (67 reviews)

Cat.No.S8605

C188-9 (TTI 101) is a potent inhibitor of STAT3 that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors.

Chemical Structure

Molecular Weight: 471.52

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	EGFR JAK Pim
Related Products	Stattic NSC 74859 (S3I-201) Cryptotanshinone (Tanshinone C) SH-4-54 BP-1-102 Napabucasin (BBI608) HO-3867 Nifuroxazide AS1517499 Homoharringtonine (HHT) STAT5-IN-1 Ochromycinone (STA-21) HJC0152 APTSTAT3-9R STAT3-IN-1 SC-1 Narciclasine SH5-07 (SH-5-07) Scutellarin Stat4 Antibody [J22G17] Ginkgolic acid C17:1 Phospho-STAT6 (Tyr641) Antibody [G7E12] Centipeda Minima Extract STAT6 Antibody [M14H14] Cucurbitacin IIb STAT1 α Antibody [J8F9] Phospho-STAT3 (Tyr705) Antibody [B17F7] SD-436 KT-333 Fritillariae Cirrhosae Bulbus Extract

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
Y79	Function assay	10 μM			28684419
SK-N-DZ	Function assay	10 μM			28684419
Huh7	Cell viability assay		48 h	IC50=11.27 μM	28533225
PLC/PRF/5	Cell viability assay		48 h	IC50=11.83 μM	28533225
HepG2	Cell viability assay		48 h	IC50=10.19 μM	28533225
SCC-35	Cell growth assay	0/0.1/0.3/1/3/10/100 μM	36 h	IC50=10.8 ± 0.0 μM	27027445
SCC-61	Cell growth assay	0/0.1/0.3/1/3/10/100 μM	36 h	IC50=14.8 ±2.9 μM	27027445
UM-SCC-17B	Cell growth assay	0/0.1/0.3/1/3/10/100 μM	36 h	IC50=0.7 ± 0.6 μM	27027445
HN30	Cell growth assay	0/0.1/0.3/1/3/10/100 μM	36 h	IC50=4.4 ± 0.1 μM	27027445
A549	Function assay		2.5 h	decreased pSTAT3 levels in a concentration-dependent manner starting at concentrations as low as 3 nM	26410177
Kasumi-1	Function assay			IC50=4.5 μM	21447830
THP-1	Function assay			IC50=4.8 μM	21447830
GDM-1	Function assay			IC50=5.0 μM	21447830
NB-1	Function assay			IC50=8.3 μM	21447830
HL-60	Function assay			IC50=5.3 μM	21447830
KG-1	Function assay			IC50=4.1 μM	21447830
K562	Apoptosis assay			induction of apoptosis with an EC50 of 43.6 μM	21447830
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	471.52	Formula	C₂₇H₂₁NO₅S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	432001-19-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	TTI 101			Smiles	COC1=CC=C(C=C1)S(=O)(=O)NC2=CC(=C(C3=CC=CC=C32)O)C4=C(C=CC5=CC=CC=C54)O

Solubility

In vitro
Batch:

DMSO : 94 mg/mL (199.35 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 2 mg/mL

Water : Insoluble

DMSO : 180 mg/mL (381.74 mM) Warmed with 50°C water bath; Ultrasonicated;
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 2 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.700mg/ml (9.97mM)	Taking the 1 mL working solution as an example, add 50 μL of 94 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	STAT3 ^[1] (Cell-free) 4.7 nM(Kd)
In vitro	C188-9 is a small-molecule inhibitor of Stat3 that targets the phosphotyrosyl peptide binding site within the Stat3 Src homology 2 (SH2) domain with Ki 136 nM. It does not inhibit upstream Jak or Src kinases^[1].
In vivo	Treatment of nude mice bearing xenografts of UM-SCC-17B, a radioresistant HNSCC line, with C188-9, but not C188, prevented tumor xenograft growth. This compound was well tolerated in mice, showed good oral bioavailability, and was concentrated in tumors^[2].
References	[1] https://pubmed.ncbi.nlm.nih.gov/25787076/ [2] https://pubmed.ncbi.nlm.nih.gov/27027445/

Applications

Methods	Biomarkers	Images	PMID
Western blot	p-STAT3 / STAT3 / CEBPδ / Myostatin / p-Akt / Akt		24011072
Immunofluorescence	VE-cadherin / β-catenin non-phosphorylated β-Catenin		26948077

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):